Featured Publications

Selective targeting of the TLR2/MyD88/NF-κB pathway reduces α-synuclein spreading in vitro and in vivo

FHL-401 | Demonstrated that FHL-401’s TLR2-MyD88 mechanism can reduce glial inflammation and decrease α-syn spreading, two key markers of Parkinson’s disease, in a mouse animal model.

Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson’s Disease via PPARα-Dependent Astrocytic GDNF Pathway

FHL-301 | Establishes that oral administration of FHL-301 protects dopaminergic neurons in an animal model of Parkinson’s disease via involvement of PPARα and GDNF.

IL-12 p40 monomer is different from other IL-12 family members to selectively inhibit IL-12Rβ1 internalization and suppress EAE

FHL-701 | Showed that FHL-701’s IL-12 based mechanism can inhibit disease processes of autoimmmune disorders in a mouse animal model.

Low-Dose Maraviroc, an Antiretroviral Drug, Attenuates the Infiltration of T Cells into the Central Nervous System and Protects the Nigrostriatum in Hemiparkinsonian Monkeys

FHL-601 | Demonstrates that FHL-601’s CCR5 mechanism can improve Parkinson’s disease markers, including protection of neurotransmitters and motor function, in a monkey animal model.

Cinnamon and its Metabolite Protect the Nigrostriatum in a Mouse Model of Parkinson’s Disease Via Astrocytic GDNF

FHL-101 | Shows that the metabolite of FHL-101 increases GDNF level, which is known to promote dopaminergic neuronal survival in cellular and animal models of Parkinson’s Disease , in mice models.

Gemfibrozil, a Lipid-Lowering Drug, Lowers Amyloid Plaque Pathology and Enhances Memory in a Mouse Model of Alzheimer’s Disease via Peroxisome Proliferator-Activated Receptor α

FHL-301 | Demonstrates that FHL-301 can lower the amyloid plaque burden in a mouse model of Alzheimer’s Disease with involvement of PPARα.

Cinnamic Acid Protects the Nigrostriatum in a Mouse Model of Parkinson’s Disease via Peroxisome Proliferator-Activated Receptorα

FHL-201 |Highlights the neuroprotective effect of FHL-201 in a mouse model of Parkinson’s disease via the PPARα pathway. Effects include normalization of striatal neurotransmitters and improved locomotor activities.

Selective disruption of TLR2-MyD88 interaction inhibits inflammation and attenuates Alzheimer’s pathology

FHL-401 | Shows that FHL-401’s TLR2-MyD88 mechanism improves disease markers in mouse animal models of various neurodegenerative disorders.

Attenuation of microglial RANTES by NEMO-binding domain peptide inhibits the infiltration of CD8+ T cells in the nigra of hemiparkinsonian monkey

FHL-501 | Discusses FHL-501’s selective inhibition of NF-κB which leads to downregulation of RANTES and eotaxin, leading to a positive response in a monkey model of Parkinson’s Disease.